232 related articles for article (PubMed ID: 15955124)
41. The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia.
Emral R; Köseoğlulari O; Tonyukuk V; Uysal AR; Kamel N; Corapçioğlu D
Exp Clin Endocrinol Diabetes; 2005 Feb; 113(2):80-4. PubMed ID: 15772898
[TBL] [Abstract][Full Text] [Related]
42. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.
Coll B; van Wijk JP; Parra S; Castro Cabezas M; Hoepelman IM; Alonso-Villaverde C; de Koning EJ; Camps J; Ferre N; Rabelink TJ; Tous M; Joven J
Eur J Pharmacol; 2006 Aug; 544(1-3):104-10. PubMed ID: 16843455
[TBL] [Abstract][Full Text] [Related]
43. Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents.
Juárez-López C; Klünder-Klünder M; Madrigal-Azcárate A; Flores-Huerta S
Pediatr Diabetes; 2013 Aug; 14(5):377-83. PubMed ID: 23438101
[TBL] [Abstract][Full Text] [Related]
44. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
Derosa G; Salvadeo SA; D'Angelo A; Fogari E; Ragonesi PD; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Arch Med Res; 2008 May; 39(4):412-9. PubMed ID: 18375253
[TBL] [Abstract][Full Text] [Related]
45. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects.
Vague P; Juhan-Vague I; Alessi MC; Badier C; Valadier J
Thromb Haemost; 1987 Jun; 57(3):326-8. PubMed ID: 3310318
[TBL] [Abstract][Full Text] [Related]
46. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.
Chappuis B; Braun M; Stettler C; Allemann S; Diem P; Lumb PJ; Wierzbicki AS; James R; Christ ER
Diabetes Metab Res Rev; 2007 Jul; 23(5):392-9. PubMed ID: 17211855
[TBL] [Abstract][Full Text] [Related]
47. Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism.
Vestergaard H; Lund S; Pedersen O
J Intern Med; 2001 Nov; 250(5):406-14. PubMed ID: 11887975
[TBL] [Abstract][Full Text] [Related]
48. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial.
Worsley R; Jane F; Robinson PJ; Bell RJ; Davis SR
Climacteric; 2015 Apr; 18(2):270-7. PubMed ID: 25333776
[TBL] [Abstract][Full Text] [Related]
49. The response of serum apolipoprotein H to an oral fat load.
Zahedi RG; Summers LK; Lumb P; Chik G; Crook MA
Ann Clin Biochem; 2004 Jul; 41(Pt 4):330-4. PubMed ID: 15298746
[TBL] [Abstract][Full Text] [Related]
50. Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.
Jucker BM; Schaeffer TR; Haimbach RE; Mayer ME; Ohlstein DH; Smith SA; Cobitz AR; Sarkar SK
Metabolism; 2003 Feb; 52(2):218-25. PubMed ID: 12601636
[TBL] [Abstract][Full Text] [Related]
51. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome.
Vine DF; Takechi R; Russell JC; Proctor SD
Atherosclerosis; 2007 Feb; 190(2):282-90. PubMed ID: 16624317
[TBL] [Abstract][Full Text] [Related]
52. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
Schreuder TC; Marsman HA; Lenicek M; van Werven JR; Nederveen AJ; Jansen PL; Schaap FG
Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G440-5. PubMed ID: 20093562
[TBL] [Abstract][Full Text] [Related]
53. Postprandial insulin response and mitochondrial oxidation in obese men nutritionally treated to lose weight.
Parra MD; Martínez de Morentin BE; Martínez JA
Eur J Clin Nutr; 2005 Mar; 59(3):334-40. PubMed ID: 15523485
[TBL] [Abstract][Full Text] [Related]
54. Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin HZ; Yang SQ; Chuckaree C; Kuhajda F; Ronnet G; Diehl AM
Nat Med; 2000 Sep; 6(9):998-1003. PubMed ID: 10973319
[TBL] [Abstract][Full Text] [Related]
55. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin.
Ye JM; Dzamko N; Cleasby ME; Hegarty BD; Furler SM; Cooney GJ; Kraegen EW
Diabetologia; 2004 Jul; 47(7):1306-1313. PubMed ID: 15232684
[TBL] [Abstract][Full Text] [Related]
56. Obesity and post-prandial lipid metabolism. Feast or famine?
Martins IJ; Redgrave TG
J Nutr Biochem; 2004 Mar; 15(3):130-41. PubMed ID: 15023394
[TBL] [Abstract][Full Text] [Related]
57. Fatty acid composition of erythrocyte phospholipids is related to insulin levels, secretion and resistance in obese type 2 diabetics on Metformin.
Enriquez YR; Giri M; Rottiers R; Christophe A
Clin Chim Acta; 2004 Aug; 346(2):145-52. PubMed ID: 15256315
[TBL] [Abstract][Full Text] [Related]
58. Relationship between altered postprandial lipemia and insulin resistance in normolipidemic and normoglucose tolerant obese patients.
Guerci B; Vergès B; Durlach V; Hadjadj S; Drouin P; Paul JL
Int J Obes Relat Metab Disord; 2000 Apr; 24(4):468-78. PubMed ID: 10805504
[TBL] [Abstract][Full Text] [Related]
59. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load.
Hiramitsu S; Miyagishima K; Ishii J; Matsui S; Naruse H; Shiino K; Kitagawa F; Ozaki Y
J Cardiol; 2012 Nov; 60(5):395-400. PubMed ID: 22890076
[TBL] [Abstract][Full Text] [Related]
60. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
